AACR Annual Meeting 2019: Past, Present, and Future of CDK4/6-targeted Therapeutics
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard...
Category: AACR
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard...
Over the course of AACR Annual Meeting 2019, there were 213 presentations on incredibly exciting clinical trials. This is...
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
The AACR-Bayer Innovation and Discovery Grants program supports researchers who are seeking to develop new treatment options for cancers...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
Persistent infections from pathogens are a major cause of cancer incidence worldwide. An analysis from 2012 indicates that more...
Recent advances in cancer research has led to enormous progress against many cancer types. From 1991 to 2015, we...
Cancer prevention refers to measures that people can take to reduce their risk of developing cancer. These measures can...
The spectacular sight of the AACR Annual Meeting 2019 Opening Ceremony, held Sunday, March 31, at the Georgia World...